HIV isolates resistant to protease inhibitor treatment have an impaired ability to replicate in thymocytes, allowing T-cell production to continue despite the peripheral T-cell decline. Understanding the basis for cellular differences in HIV replication might teach us new ways to protect the immune system from highly pathogenic strains of HIV-1 (pages 712–718).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kaufman, D., Panteleo, G., Sudre, P. & Telenti, A. CD4-cell count in HIV-1 infected individuals remaining viremic with highly active anti-retroviral therapy (HAART). Swiss HIV cohort study. Lancet 251, 723–724 (1998).
Stoddart, C.A. et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nature Med. 7, 712–718 (2001).
Zhang, Y-M. et al. Drug-resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. J. Virol. 71, 6662–6670 (1997).
Croteau, G. et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71, 1089–1106 (1997).
Penn, M.L. et al. Primary and recombiant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res. Hum. Retroviruses 17, 517–523 (2001).
Ramarli, D., Fox, D.A. & Reinherz, E.L. Selective inhibition of interleukin-2 gene function following thymic antigen/major histocompatibility complex receptor cross-linking: possible thymic selection mechanisms. Proc. Natl. Acad. Sci. USA 84, 8598–8603 (1987).
Yang, S.Y., Denning, S.M., Mizuno, S., Dupont, B. & Haynes, B.F. A novel activation pathway for mature thymocytes: Costimulation of CD2 (T,p50) and CD28 (T,p44) induces autocrine interleukin 2/interleukin-2 receptor-mediated cell proliferation. J. Exp. Med. 168, 1457–1468 (1988).
Chen, D. & Rothenberg, E.V. Molecular basis for development changes in interleukin-2 gene inducibility. Mol. Cell. Biol. 13, 228–237 (1993).
Chen, F., Chen, D. & Rothenberg, E.V. Specific regulation of Fos family transcription factors in thymocytes at two development checkpoints. Internat. Immunol. 11, 677–688 (1999).
Su, L. et al. HIV-1 induced thymocyte depletion is associated with indirect cytopathicity and infection of progenitor cells in vivo. Immunity 2, 25–36 (1995).
Fauci, A.S. Host factors and the pathogenesis of HIV-induced disease. Nature 384, 529–534 (1996).
Sempowski, G.D. et al. Leukemia inhibitory factor, oncostatin M, IL-6, and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy. J. Immunol. 164, 2180–2187 (2000).
Haynes, B.F., Markert, M.L., Sempowski, G.D., Patel, D.D. & Hale, L.P. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Ann. Rev. Immunol. 18, 529–560 (2000).
Kitchen, S.G. & Zack, J.A. CXCR4 expression during lymphopoiesis: Implications for human immunodeficiency virus type 1 infection of the thymus. J. Virol. 71, 6928–2934 (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haynes, B., Sempowski, G. Can the thymus win the battle against drug-resistant HIV?. Nat Med 7, 661–662 (2001). https://doi.org/10.1038/89028
Issue Date:
DOI: https://doi.org/10.1038/89028
